These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9755725)

  • 1. Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia.
    Hodgkiss RJ
    Anticancer Drug Des; 1998 Sep; 13(6):687-702. PubMed ID: 9755725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography.
    Aboagye EO; Kelson AB; Tracy M; Workman P
    Anticancer Drug Des; 1998 Sep; 13(6):703-30. PubMed ID: 9755726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous triple staining for hypoxia, proliferation, and DNA content in murine tumours.
    Webster L; Hodgkiss RJ; Wilson GD
    Cytometry; 1995 Dec; 21(4):344-51. PubMed ID: 8608732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside.
    Urtasun RC; Parliament MB; McEwan AJ; Mercer JR; Mannan RH; Wiebe LI; Morin C; Chapman JD
    Br J Cancer Suppl; 1996 Jul; 27():S209-12. PubMed ID: 8763882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors.
    Overgaard J
    Oncol Res; 1994; 6(10-11):509-18. PubMed ID: 7620219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia.
    Olive PL; Durand RE; Raleigh JA; Luo C; Aquino-Parsons C
    Br J Cancer; 2000 Dec; 83(11):1525-31. PubMed ID: 11076663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection.
    Hodgkiss RJ; Jones G; Long A; Parrick J; Smith KA; Stratford MR; Wilson GD
    Br J Cancer; 1991 Jan; 63(1):119-25. PubMed ID: 1989649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.
    Ebbesen P; Pettersen EO; Gorr TA; Jobst G; Williams K; Kieninger J; Wenger RH; Pastorekova S; Dubois L; Lambin P; Wouters BG; Van Den Beucken T; Supuran CT; Poellinger L; Ratcliffe P; Kanopka A; Görlach A; Gasmann M; Harris AL; Maxwell P; Scozzafava A
    J Enzyme Inhib Med Chem; 2009 Apr; 24 Suppl 1():1-39. PubMed ID: 19330638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts.
    Lord EM; Harwell L; Koch CJ
    Cancer Res; 1993 Dec; 53(23):5721-6. PubMed ID: 8242628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Some aspects of the metabolism of misonidazole.
    Flockhart IR; Malcolm SL; Marten TR; Parkins CS; Ruane RJ; Troup D
    Br J Cancer Suppl; 1978 Jun; 3():264-7. PubMed ID: 277244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?
    Yaromina A; Hölscher T; Eicheler W; Rosner A; Krause M; Hessel F; Petersen C; Thames HD; Baumann M; Zips D
    Radiother Oncol; 2005 Aug; 76(2):206-12. PubMed ID: 16024121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
    Vordermark D; Brown JM
    Strahlenther Onkol; 2003 Dec; 179(12):801-11. PubMed ID: 14652668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel fluorescent markers for hypoxic cells of naphthalimides with two heterocyclic side chains for bioreductive binding.
    Liu Y; Xu Y; Qian X; Liu J; Shen L; Li J; Zhang Y
    Bioorg Med Chem; 2006 May; 14(9):2935-41. PubMed ID: 16403640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Nitroimidazole-tricarbocyanine conjugate as a near-infrared fluorescent probe for in vivo imaging of tumor hypoxia.
    Okuda K; Okabe Y; Kadonosono T; Ueno T; Youssif BG; Kizaka-Kondoh S; Nagasawa H
    Bioconjug Chem; 2012 Mar; 23(3):324-9. PubMed ID: 22335430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel fluorinated hypoxia-targeted compounds as Non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS).
    Papadopoulou MV; Ji M; Bloomer WD
    Anticancer Res; 2006; 26(5A):3253-8. PubMed ID: 17094437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioreductive fluorescent markers for hypoxic cells: a study of 2-nitroimidazoles with 1-substituents containing fluorescent, bridgehead-nitrogen, bicyclic systems.
    Hodgkiss RJ; Middleton RW; Parrick J; Rami HK; Wardman P; Wilson GD
    J Med Chem; 1992 May; 35(10):1920-6. PubMed ID: 1588568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas.
    Raleigh JA; Chou SC; Calkins-Adams DP; Ballenger CA; Novotny DB; Varia MA
    Clin Cancer Res; 2000 Mar; 6(3):855-62. PubMed ID: 10741707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma.
    Varia MA; Calkins-Adams DP; Rinker LH; Kennedy AS; Novotny DB; Fowler WC; Raleigh JA
    Gynecol Oncol; 1998 Nov; 71(2):270-7. PubMed ID: 9826471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational exchange in pimonidazole--a hypoxia marker.
    Gabellieri C; Eykyn TR; Leach MO
    Magn Reson Chem; 2007 Aug; 45(8):621-3. PubMed ID: 17559161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas.
    Wijffels KI; Marres HA; Peters JP; Rijken PF; van der Kogel AJ; Kaanders JH
    Oral Oncol; 2008 Apr; 44(4):335-44. PubMed ID: 17689286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.